Vol. 56 No. 40
Saturday, October 2, 2021
BSA Postpones Decision on Special Permit for 801 Co-op City Blvd. Developers asked to address several issues before next hearing date BY BRANDON ORTIZ
The New York City Board of Standards and Appeals held a review session and heard testimony from the public on Monday, Sept. 27, to discuss a special permit that would potentially reduce street parking by 54 spots at 801 Co-op City Boulevard – not 100 as originally suggested. The BSA did not reach a final decision on Monday during their review because the BSA Board brought up concerns about the application which they felt needed to be addressed first before reaching a final decision. Developers of the new diagnostic treatment center, which is being constructed next to Bay Park Nursing Home, will now have five weeks to submit the necessary edits requested by the BSA. A follow-up hearing could potentially take place in eight weeks, BSA Chair Margery Perlmutter told Todd Dale, Esq., who represents the developers of the diagnostic treatment center constructed at the location. In total, the BSA has asked the developers to revise or add to five aspects of (Continued on page 2)
Co-op City Metro North Station Update (See page 3)
Janitorial Services Spruce Up Building 18 Basement and Laundry Room
$1.25
Facts Matter President’s Report
Bernard Cylich A headline in the Co-op City Times of September 25 reads: “Shareholders Object to Inclusion of Waterfront Park Funding in 2022 Carrying Charge Increase.” And the article continues: “The speakers objected to the increase citing the ongoing pandemic and its financial impact on their household.” Have our cooperators been financially impacted by the “ongoing pandemic?” As the saying goes, the devil is in the details: None of the 18 speakers who spoke at HCR’s virtual carrying charge conference with Co-op City shareholders on September 21, five of whom are Board members, provided any documentation to substantiate their claims. (Continued on page 4)
Riverbay Safety Department’s Mold Program The Riverbay Safety Department oversees the corporation’s mold program throughout Co-op City. In the event a shareholder observes mold in an apartment, a call must be placed to the respective Cooperator Services Office (CSO) requesting a mold assessment which will be conducted by the Safety Department. Once an assessment is completed and it is determined that mold is present, an investigation will begin to determine the cause of the mold. When the cause of the mold is identified and corrected, then the Safety Department will schedule an appointment to remediate the visual mold in accordance with the regulations. Mold vs. Mildew Mildew: Usually grows in a flat pattern and appears either powdery or fluffy. It can be easily identified as a patch of white, gray, or yellowish fungus that is lying on the surface of a moist area. Mildew usually turns black or brown over time. Mildew can grow on any organic matter such as wood, walls and wallpaper and is caused by humidity and moisture. During the winter months, when the heat goes full blast and the windows stay shut, mildew can flourish, and, as the weather warms up outside, humidity can also help the mildew process along. Mold: Usually fuzzy or slimy in appearance. It appears as irregularly shaped spots that can have different colors. Oftentimes, surfaces that are covered in mold begin to rot. Most typical indoor air exposures to mold do not present a risk of adverse health effects. Molds can cause adverse effects by producing (Continued on page 8)
CDC Aligns With FDA on Booster Shot Recommendations BY BRANDON ORTIZ
The basement and laundry room of Building 18 got a plaster and paint job on Friday, Sept. 24. Building Services staff Matos, Damien, Richard and Bolivar plastered the area, cleaned and painted the basement floor and laundry room, giving the facility a facelift. This work is being done in buildings throughout the development as Building Services continues to ensure residential buildings remain spic and span for the enjoyment of Co-op City shareholders and their guests. Shareholders are reminded to do their part by picking up after themselves and keeping the floor and machines clean. Photos by Luis Lopez
Last Wednesday, September 22, the FDA announced that Pfizer BioNTech will be the first of the vaccine distributors to offer a booster shot. Before the FDA could officially extend its emergency use authorization to include the single booster dose of the Pfizer BioNTech COVID-19 vaccine (a.k.a. Comirnaty), the CDC had to endorse the decision as well. Fortunately, that confirmation came swiftly, as a few days later, on Friday, Sept. 24, the CDC officially announced its endorsement of the Comirnaty booster dose. Originally, the Advisory Committee on Immunization Practices (ACIP) advised the CDC to make booster shots available for only Americans 65 and older and those with underlying health conditions. But, Dr. Rochelle Walensky, CDC Director, added another demographic to the list last Friday – workers who are put at a higher risk of exposure to the virus because of their occupation will be eligible for a booster shot six months after their second dose too. Both the CDC and FDA strongly recommend older Americans, namely individuals 50 years and older, get their booster dose. Data of Comirnaty’s effectiveness after six months showed a general decline in the vaccine’s capability to fend off an infection, according to the CDC. Fortunately, a booster dose solves that issue. Equally important, both the CDC and FDA do not recommend mixing doses. Individuals who received the Moderna or Johnson and Johnson vaccine should (Continued on page 4)